Dr. Campadelli Fiume's research focuses on the molecular basis of herpes simplex virus (HSV) entry into susceptible cells, and on engineering of candidate oncolytic HSVs retargeted to tumor-specific receptors. HSV entry is a multistep process. First, gD binds to one of its receptors and triggers virion-cell fusion. Fusion is executed by the conserved glycoproteins gH/gL and gB. Major accomplishments by the labs were the discovery of nectin as HSV receptor, and the triggering activity of receptor-bound gD, including the identification of gD profusion domain. Current aims include identification of the role of gH/gL in fusion. Starting from this background we have modified gD and re-addressed this molecule to the tumor-specific receptor HER-2. She has provided the first proof of principle evidence that retargeted HSVs exert antitumor activity in vivo.